Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) – Stock analysts at Wedbush boosted their Q3 2016 EPS estimates for shares of Eiger BioPharmaceuticals in a note issued to investors on Wednesday. Wedbush analyst H. Behanna now expects that the firm will earn ($1.06) per share for the quarter, up from their prior forecast of ($1.15). Wedbush currently has a “Outperform” rating and a $36.00 target price on the stock. Wedbush also issued estimates for Eiger BioPharmaceuticals’ Q4 2016 earnings at ($1.00) EPS, FY2016 earnings at ($6.54) EPS, Q1 2017 earnings at ($1.06) EPS, Q2 2017 earnings at ($0.77) EPS, Q3 2017 earnings at ($0.82) EPS, Q4 2017 earnings at ($0.86) EPS, FY2017 earnings at ($3.50) EPS, FY2018 earnings at ($3.54) EPS, FY2019 earnings at ($3.10) EPS and FY2020 earnings at ($4.55) EPS.
Several other research firms also recently weighed in on EIGR. Oppenheimer Holdings Inc. started coverage on Eiger BioPharmaceuticals in a research report on Tuesday, July 5th. They issued an “outperform” rating and a $34.00 target price for the company. Zacks Investment Research downgraded Eiger BioPharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, June 7th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $34.50.
Eiger BioPharmaceuticals (NASDAQ:EIGR) opened at 13.39 on Monday. The stock’s 50 day moving average is $15.11 and its 200 day moving average is $18.45. Eiger BioPharmaceuticals has a 12-month low of $12.90 and a 12-month high of $28.35. The firm’s market cap is $95.12 million.
Eiger BioPharmaceuticals (NASDAQ:EIGR) last posted its quarterly earnings data on Wednesday, August 10th. The company reported ($1.87) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.17) by $0.70.
In related news, insider James P. Shaffer acquired 3,125 shares of the firm’s stock in a transaction dated Thursday, August 18th. The stock was acquired at an average price of $15.70 per share, for a total transaction of $49,062.50. Following the purchase, the insider now owns 5,620 shares of the company’s stock, valued at approximately $88,234. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Ventures Fund Vi L.P. Vivo acquired 187,500 shares of the firm’s stock in a transaction dated Thursday, August 18th. The stock was bought at an average price of $16.00 per share, with a total value of $3,000,000.00. The disclosure for this purchase can be found here. 27.20% of the stock is owned by insiders.
Several institutional investors have recently made changes to their positions in EIGR. BlackRock Institutional Trust Company N.A. bought a new position in shares of Eiger BioPharmaceuticals during the first quarter valued at about $261,000. Sabby Management LLC bought a new position in shares of Eiger BioPharmaceuticals during the first quarter valued at about $4,354,000. Sphera Funds Management LTD. bought a new position in shares of Eiger BioPharmaceuticals during the first quarter valued at about $2,474,000. Jacobs Levy Equity Management Inc. bought a new position in shares of Eiger BioPharmaceuticals during the first quarter valued at about $251,000. Finally, Vivo Capital LLC bought a new position in shares of Eiger BioPharmaceuticals during the first quarter valued at about $26,825,000. Institutional investors and hedge funds own 37.83% of the company’s stock.
Eiger BioPharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Receive News & Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.